Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings

Executive Summary

Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said

You may also be interested in...

“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says

"Project BioShield" offers a model that policymakers should consider to encourage research in infectious diseases, FDA Commissioner McClellan told the Commonwealth Club in San Francisco June 9

Drug R&D For Global Diseases Needs Revenue Incentives – BIO Meeting

Development of vaccines for diseases prevalent in the developing world would be most effectively promoted by revenue-enhancing incentives, speakers at a Biotechnology Industry Association/Bill & Melinda Gates Foundation forum said

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts